Columbia Threadneedle Investments
VC Fund
London, United Kingdom
Columbia Threadneedle Investments is a VC fund in London focused on Biotechnology and Health Care. As a leading global asset manager, our consistent, collaborative investment approach allows you to deliver the dependable experience your clients demand.Investors want strong, repeatable risk-adjusted returns. Consistency — not surprises. So, how do we deliver a consistent investment experience?Better insightsOur talented investment teamswork together to uncover investment insights from around the world. By sharing knowledge across asset classes and geographies we generate richer perspectives on global, regional and local investment landscapes.Better decisionsWe foster a culture of diversity. The ability to exchange and debate investment ideas in a collaborative and diverse environment enriches our teams’ investment processes. More importantly, it results in better informed investment decisions for our clients.Better outcomesOur broad range of investment strategies and solutions are designed to meet the evolving needs of financial advisors like you, and your clients.The sum of our partsTwo is stronger than one — a fact reinforced in 2015 when Columbia Management and London-based Threadneedle Investments came together as Columbia Threadneedle Investments. By combining our global insight, research capabilities and investment expertise, you and your clients have access to the best of both firms.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Columbia Threadneedle Investments invests in
Stages Columbia Threadneedle Investments invests in
Countries Columbia Threadneedle Investments invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Jessop
|
|||
Investment Focus
Industry
- Biotechnology 16 (67%)
- Health Care 13 (54%)
- Therapeutics 8 (33%)
- Pharmaceutical 8 (33%)
- Biopharma 6 (25%)
Stage
- Post-IPO Equity 16 (67%)
- Series C 3 (13%)
- Private Equity 2 (8%)
Country
- United States 12 (50%)
- China 2 (8%)
- Germany 2 (8%)
- Canada 1 (4%)
- France 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Jessop
Head of Investment Risk
|
Head of Investment Risk | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jasper Therapeutics
|
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $132M / Post-IPO Equity / Jul 16, 2026 | |
Cue Biopharma
|
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen-presentingcells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic.Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology, and immuno-oncology. | $50M / Post-IPO Equity / Jul 09, 2026 | |
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $100M / Post-IPO Equity / Jun 24, 2026 | |
NRx Pharmaceuticals
|
NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. It addresses life-threatening diseases that often go untreated by researching, developing, and scaling solutions to help people who most desperately need them.The company hasannounced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure, and is also developing NRX-100/101 which is the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLifeR COVID vaccine developed by the Israel Institute for Biological Research. | $22.3M / Post-IPO Equity / Jun 03, 2026 | |
Assembly Biosciences
|
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome.Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $115M / Post-IPO Equity / May 22, 2026 | |
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | |
InflaRx
|
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany. | $150M / Post-IPO Equity / May 06, 2026 | |
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M / Post-IPO Equity / Apr 16, 2026 | |
Adagene
|
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. | $70M / Post-IPO Equity / Apr 02, 2026 | |
Relmada Therapeutics
|
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M / Post-IPO Equity / Mar 09, 2026 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Columbia Threadneedle Investments invest in?
Columbia Threadneedle Investments invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series C stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Columbia Threadneedle Investments?
Public channels for Columbia Threadneedle Investments include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Columbia Threadneedle Investments?
The team at Columbia Threadneedle Investments includes David Jessop (Head of Investment Risk). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
